| CAS: | 23598-72-3 | ||||
| 分子式: | C11H8ClNO3 | ||||
| 分子量: | 237.64 | ||||
| 中文名称: |
| ||||
| 英文名称: |
| ||||
| 生产方法: | 用邻氯苯甲醛与盐酸羟胺在碱性条件下肟化,生成邻氯苯甲肟,然后以氯气氯化得邻氯苯甲肟氯,与乙酰乙酸乙酯在碱作用下环合得3-邻氯苯基-5-甲基-4-异噁唑羧酸乙酯,最后以碱液水解并酸化制得该品。 | ||||
| 用途: | 氯苯唑青霉素钠的中间体。 |
| 货号 | 品牌 | 产品名称 | 规格 | 包装、参考价格 | |||||||||||||||||||||||||||||||||||||||||
| C916620 | MACKLIN | 3-(2-氯苯基)-5-甲基异唑-4-羧酸 | 98% | 41元/1g; 123元/5g; 534元/25g; | 咨询 | ||||||||||||||||||||||||||||||||||||||||
储存:室温 | |||||||||||||||||||||||||||||||||||||||||||||
| L06240 | Alfa Aesar | 3-(2-Chlorophenyl)-5-methylisoxazole-4-carboxylic acid | 98% | 291元/10g; 1174元/50g; 4118元/250g; | 咨询 | ||||||||||||||||||||||||||||||||||||||||
基本信息 MDL EINECS 分子式 分子量 熔点 形态 Beilstein GHS危害和防范说明 GHS符号 Hazard Statements Precautionary Statements 安全信息 危险类别 安全等级 TSCA | |||||||||||||||||||||||||||||||||||||||||||||
| S527661 | 3-(2-CHLOROPHENYL)-5-METHYL-4-ISOXAZOLECARBOXYLIC ACID | AldrichCPR | 1908.94元/250MG; | 咨询 | |||||||||||||||||||||||||||||||||||||||||
产品说明 其他说明 Please note that sigma-aldrich provides this product to early discovery researchers as part of a collection of rare and unique chemicals. sigma-aldrich does not collect analytical data for this product. Buyer assumes responsibility to confirm product identity and/or purity. All sales are final. 基本信息
| |||||||||||||||||||||||||||||||||||||||||||||
| 1144951 | USP | Cloxacillin Related Compound D | United States Pharmacopeia (USP) Reference Standard | 11011.4元/15 MG; | 咨询 | ||||||||||||||||||||||||||||||||||||||||
产品说明 一般描述 This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including MSDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia. 分析说明 These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind. 其他说明 USP issued SDS can be found here. 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||||||||||||||
| 303616 | Fluorochem | 3-(2-Chlorophenyl)-5-methylisoxazole-4-carboxylic acid | 95% | 1078元/1g; 4136元/5g; | 咨询 | ||||||||||||||||||||||||||||||||||||||||
基本信息
安全信息
| |||||||||||||||||||||||||||||||||||||||||||||
| HY-W070660R | MCE | 3-(2-Chlorophenyl)-5-methylisoxazole-4-carboxylic acid (Standard),23598-72-3,3-(2-氯苯基)-5-甲基-4-异噁唑羧酸 (标准品)_MCE(MedChemExpress) | 咨询 | ||||||||||||||||||||||||||||||||||||||||||
MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。 3-(2-Chlorophenyl)-5-methylisoxazole-4-carboxylic acid (Standard)MCE 国际站:3-(2-Chlorophenyl)-5-methylisoxazole-4-carboxylic acid (Standard) 品牌:MedChemExpress (MCE) 货号:HY-W070660R CAS 号:23598-72-3 产品简介:3-(2-Chlorophenyl)-5-methylisoxazole-4-carboxylic acid (Standard) 是 3-(2-Chlorophenyl)-5-methylisoxazole-4-carboxylic acid 的分析标准品。本产品用于研究及分析应用。 产品应用:该化合物为分析标准品级别,是含量检测的分析标准品,常用于液相、气相和质谱的定性、定量及方法学研究实验中。 分子量:237.64 Formula:C11H8ClNO3 中文名称:3-(2-氯苯基)-5-甲基-4-异噁唑羧酸 (标准品) 运输条件:美国大陆地区的室温;其他地区可能有所不同。 储存方式:请按照分析证书中推荐的条件储存产品。 提供质量检测报告:产品使用指南 产品活性:3-(2-Chlorophenyl)-5-methylisoxazole-4-carboxylic acid (Standard) 是 3-(2-Chlorophenyl)-5-methylisoxazole-4-carboxylic acid 的分析标准品。本产品用于研究及分析应用。 相关产品:1-Methylhistamine dihydrochloride (Standard) | Linolelaidic acid (Standard) | Palmitoylglycine (Standard) | Remimazolam impurity 4 (Standard) | 16-Hydroxyhexadecanoic acid (Standard) | Tetraxetan (Standard) | 5,7-Dihydroxycoumarin (Standard) | 4-Nitrocatechol (Standard) | DL-Pantolactone (Standard) | trans-Platinum(II)diammine dichloride (Standard) | Cyclo-(Pro-Gly) (Standard) | 2-Cyanoethyl acetoacetate (Standard) 热门产品线:抑制剂 | 稳定性同位素标记物 | 脂质 | 糖类 Trending products:Inhibitors | Isotope-Labeled Compounds | Lipids | Saccharides MCE 抑制剂: MedChemExpress 信号通路产品覆盖细胞凋亡、自噬、细胞周期与 DNA 损伤、表观遗传、GPCR/G 蛋白、免疫与炎症、JAK/STAT、MAPK/ERK、膜转运体与离子通道、代谢酶与蛋白酶、神经信号、NF-κB、PI3K/Akt/mTOR、PROTAC、蛋白酪氨酸激酶/受体酪氨酸激酶、干细胞/Wnt、TGF-β/Smad 及维生素 D/核受体等研究方向,为肿瘤、感染、炎症与免疫、神经系统疾病、代谢性疾病、心血管疾病和内分泌研究提供多维度的产品选择,助力客户发表文献超 80,000 篇。 相关产品可根据具体情况提供化学结构、作用靶点、生物活性、纯度、溶解度、体内外研究信息、参考文献及质量分析报告 (COA)等资料。 客户发表文献: 品牌介绍:
| |||||||||||||||||||||||||||||||||||||||||||||